Efficacia e sicurezza di depemokimab rispetto a mepolizumab negli adulti con granulomatosi eosinofila con poliangioite recidivante o refrattaria (EGPA) (OCEAN)
Uno studio di 52 settimane, randomizzato, in doppio cieco, double-dummy, a gruppi paralleli, multicentrico, di non inferiorità per indagare l'efficacia e la sicurezza di depemokimab rispetto a mepolizumab negli adulti con granulomatosi eosinofila recidivante o refrattaria con poliangioite (EGPA) ) Ricevere una terapia standard di cura (SoC).
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Luoghi di studio
-
-
-
La Plata, Argentina, B1900
- GSK Investigational Site
-
San Miguel de Tucumán, Argentina, T4000
- GSK Investigational Site
-
-
-
-
Styria
-
Graz, Styria, Austria, 8036
- GSK Investigational Site
-
-
-
-
-
Santo André, Brasile, 09060-870
- GSK Investigational Site
-
São Paulo, Brasile, 4023900
- GSK Investigational Site
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 3A9
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5T 3L9
- GSK Investigational Site
-
-
-
-
-
Beijing, Cina, 100005
- GSK Investigational Site
-
Guangzhou, Cina, 510163
- GSK Investigational Site
-
Hefei, Cina, 230001
- GSK Investigational Site
-
Nanjing, Cina, 210006
- GSK Investigational Site
-
Qingdao, Cina, 266071
- GSK Investigational Site
-
Shanghai, Cina, 200032
- GSK Investigational Site
-
Shenzhen, Cina, 518020
- GSK Investigational Site
-
Wenzhou, Cina, 325000
- GSK Investigational Site
-
-
-
-
-
Gwangju, Corea del Sud, 61469
- GSK Investigational Site
-
Seoul, Corea del Sud, 06351
- GSK Investigational Site
-
Seoul, Corea del Sud, 06591
- GSK Investigational Site
-
Seoul, Corea del Sud, 05505
- GSK Investigational Site
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Corea del Sud, 3080
- GSK Investigational Site
-
-
-
-
-
Brest, Francia, 29609
- GSK Investigational Site
-
La Roche-sur-Yon, Francia, 85925
- GSK Investigational Site
-
Nantes, Francia, 44093
- GSK Investigational Site
-
Paris, Francia, 75014
- GSK Investigational Site
-
-
-
-
-
Freiburg im Breisgau, Germania, 79106
- GSK Investigational Site
-
Minden, Germania, 32429
- GSK Investigational Site
-
-
-
-
-
Kanagawa, Giappone, 252-0392
- GSK Investigational Site
-
Kanagawa, Giappone, 247-8533
- GSK Investigational Site
-
Saitama, Giappone, 350-8550
- GSK Investigational Site
-
Tokyo, Giappone, 181-8611
- GSK Investigational Site
-
Tokyo, Giappone, 162-8666
- GSK Investigational Site
-
-
-
-
-
Ramat Gan, Israele, 52621
- GSK Investigational Site
-
-
-
-
-
Bari, Italia, 70124
- GSK Investigational Site
-
Brescia, Italia, 25123
- GSK Investigational Site
-
Florence, Italia, 50134
- GSK Investigational Site
-
Milan, Italia, 20132
- GSK Investigational Site
-
Milan, Italia, 20162
- GSK Investigational Site
-
Pavia, Italia, 27100
- GSK Investigational Site
-
Pisa, Italia, 56126
- GSK Investigational Site
-
Roma, Italia, 00128
- GSK Investigational Site
-
Torrette AN, Italia, 60126
- GSK Investigational Site
-
Treviso, Italia, 31100
- GSK Investigational Site
-
-
-
-
-
Groningen, Olanda, 9713 GZ
- GSK Investigational Site
-
Leiden, Olanda, 2333 ZA
- GSK Investigational Site
-
-
-
-
-
Gdansk, Polonia, 80-952
- GSK Investigational Site
-
Lodz, Polonia, 90-153
- GSK Investigational Site
-
Warsaw, Polonia, 01-138
- GSK Investigational Site
-
-
-
-
-
Lisbon, Portogallo, 1649-035
- GSK Investigational Site
-
Porto, Portogallo, 4099-001
- GSK Investigational Site
-
-
-
-
-
Birmingham, Regno Unito, B15 2GW
- GSK Investigational Site
-
London, Regno Unito, SE1 7EH
- GSK Investigational Site
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Regno Unito, CB2 2QQ
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spagna, 08036
- GSK Investigational Site
-
Barcelona, Spagna, 08035
- GSK Investigational Site
-
Granada, Spagna, 18014
- GSK Investigational Site
-
Pamplona, Spagna, 31008
- GSK Investigational Site
-
Zaragoza, Spagna, 50009
- GSK Investigational Site
-
-
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80206
- GSK Investigational Site
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32610
- GSK Investigational Site
-
-
Minnesota
-
Rochester, Minnesota, Stati Uniti, 55905-0001
- GSK Investigational Site
-
-
New York
-
New York, New York, Stati Uniti, 10021-4823
- GSK Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28211
- GSK Investigational Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15261
- GSK Investigational Site
-
-
-
-
-
Malmö, Svezia, SE-205 02
- GSK Investigational Site
-
-
-
-
-
Budapest, Ungheria, 1023
- GSK Investigational Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Participant (male or female) must be 18 years of age or older at the time of signing the informed consent.
- Participants who are >=40 kilogram at Screening Visit 1.
- Participants with a documented diagnosis of EGPA for at least 6 months based on the history or presence of: asthma plus eosinophilia defined as >1.0*10^9/Liter (L) and/or >10 percentage (%) of leucocytes plus at least 2 of the following additional features of EGPA: a biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation, neuropathy, mono or poly (motor deficit or nerve conduction abnormality), pulmonary infiltrates, non-fixed, sino-nasal abnormality, cardiomyopathy (established by echocardiography or magnetic resonance imaging), glomerulonephritis (hematuria, red cell casts, proteinuria), alveolar hemorrhage (by bronchoalveolar lavage), palpable purpura, anti-neutrophil cytoplasmic antibodies positive Myeloperoxidase or Proteinase 3.
- History of relapsing OR refractory disease.
- Participants must be on a stable dose of oral prednisolone or prednisone of >=7.5 mg/day (but not >50 mg/day) or equivalent for at least 4 weeks prior to Baseline (Visit 2).
- If participants receiving immunosuppressive therapy (excluding cyclophosphamide) the dosage must be stable for the 4 weeks prior to Baseline (Visit 2) and during the study.
- A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of non-childbearing potential (WONCBP) OR Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of <1%.
- Capable of giving signed informed consent
Exclusion Criteria:
- Participants diagnosed with granulomatosis with polyangiitis; previously known as Wegener's granulomatosis or microscopic polyangiitis.
- Participants with organ-threatening EGPA as per EULAR criteria,
- Imminently life-threatening EGPA disease within 3 months prior to Screening (Visit 1).
- A current malignancy or previous history of cancer in remission for less than 12 months prior to Screening.
- Participants with alanine aminotransferase >2*upper limit of normal (ULN) or if participant is on background methotrexate or azathioprine >3*ULN, aspartate aminotransferase >2*ULN or if participant is on background methotrexate or azathioprine >3*ULN, alkaline phosphatase >=2.0*ULN, total bilirubin >1.5*ULN (isolated bilirubin >1.5*ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%), Cirrhosis or current unstable liver or biliary disease per investigator assessment.
- Participants who have severe or clinically significant cardiovascular disease uncontrolled with standard treatment.
- Participants who have known, pre-existing, clinically significant system abnormalities that are not associated with EGPA and are uncontrolled with standard treatment.
- Clinically significant abnormality in the hematological, biochemical or urinalysis screen at Visit 1.
- Chronic or ongoing active infectious disease requiring systemic treatment.
- Participants with a known, pre-existing parasitic infestation within 6 months prior to Screening Visit 1.
- A known immunodeficiency (e.g., human immunodeficiency virus [HIV]).
- Participants that, according to the investigator's medical judgment, are likely to have active coronavirus disease 2019 (COVID-19) infection. Participants with known COVID-19 positive contacts within the past 14 days must be excluded for at least 14 days following the exposure during which the participant must remain symptom-free.
- Participants with a known allergy or intolerance to a monoclonal antibody or biologic therapy or any of the excipients of the investigational products.
- Participants who have a previous documented failure with anti-Interleukin-5 /Interleukin-5 receptor therapy (e.g., mepolizumab, reslizumab, benralizumab). Participants who have received monoclonal antibodies (mAb) and who have not undergone the required washout periods, prior to Visit 1.
- Participants receiving any of the following: Oral corticosteroids: Participant requires an oral corticosteroid dose of >50 mg/day prednisolone/prednisone in the 4-week period prior to Baseline (Visit 2), Intravenous (IV), intramuscular or subcutaneous (SC) corticosteroids in the 4-week period prior to Baseline (Visit 2), Omalizumab within 130 days prior to Screening (Visit 1), Cyclophosphamide (CYC): oral CYC within 4 weeks prior to Baseline (Visit 2) and IV CYC within 3 weeks prior to Baseline (Visit 2), if their total white blood cells is >=4*10^9/L (measured using the local laboratory if necessary), Rituximab within 12 months prior to Screening (Visit 1); in addition, the Participant must have shown recovery of peripheral B-cell count to within the normal range, Tezepelumab and Dupilumab with a washout period of 5 half-lives prior to Screening Visit 1, IV or SC immunoglobulin within 6 months prior to Screening (Visit 1); For China and Japan only within 12 weeks prior to Screening (Visit 1), Interferon-alpha within 6 months prior to Screening Visit 1, Anti-tumor necrosis factor therapy within 12 weeks prior to Screening Visit 1, Anti-CD52 (alemtuzumab) within 6 months prior to Screening Visit 1.
- Participants with QT interval corrected for heart rate according to Fridericia's formula (QTcF) >=450 milliseconds (msec) or QTcF >=480 msec for participants with Bundle Branch Block in the 12-lead ECG central over-read from at Screening Visit 1.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Partecipanti che hanno ricevuto depemokimab + placebo corrispondente a mepolizumab
|
Depemokimab will be administered Placebo matching to mepolizumab will be administered. |
|
Comparatore attivo: Partecipanti che hanno ricevuto mepolizumab + placebo corrispondente a depemokimab
|
Mepolizumab will be administered Placebo matching to depemokimab will be administered. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of participants with remission (Birmingham Vasculitis Activity Score [BVAS] =0 and a dose of oral corticosteroid [OCS] less than or equal to [<=] 4 milligram [mg] per day)
Lasso di tempo: Up to Week 52
|
Participants must be in remission at both Weeks 36 and 52. |
Up to Week 52
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Numero di partecipanti che hanno ottenuto la remissione utilizzando la definizione della European League against Rheumatism (EULAR) (BVAS = 0 e OCS <=7,5 mg/giorno) alle settimane 36 e 52
Lasso di tempo: Alle settimane 36 e 52
|
Alle settimane 36 e 52
|
|
|
Numero di partecipanti con remissione (BVAS=0 e OCS <=7,5 mg/giorno) entro le prime 24 settimane con remissione continua fino alla settimana 52
Lasso di tempo: Fino alla settimana 52
|
Fino alla settimana 52
|
|
|
Numero di partecipanti che raggiungono la remissione (BVAS = 0 e OCS ≤ 4 mg/giorno) entro le prime 24 settimane con remissione continuata fino alla settimana 52
Lasso di tempo: Fino alla Settimana 52
|
Fino alla Settimana 52
|
|
|
Number of participants in each category of accrued duration of remission
Lasso di tempo: Up to Week 52
|
Total accrued duration of remission is the accrued number of weeks where BVAS = 0 plus OCS dose <= 4 mg/day over the 52-week intervention period. The accrued duration was categorized into zero, >0 to <12 weeks, 12 to <24 weeks, 24 to <36 weeks or more than or equal to (>=) 36 weeks. |
Up to Week 52
|
|
Number of participants with total accrued duration of remission
Lasso di tempo: Up to Week 52
|
Total accrued duration of remission is the accrued number of weeks where BVAS = 0 plus OCS dose <= 4 mg/day over the 52-week intervention period. |
Up to Week 52
|
|
Time to first EGPA relapse
Lasso di tempo: Up to Week 52
|
The time to first EGPA relapse will be calculated from the date of first dose of study intervention and start date of the EGPA relapse. |
Up to Week 52
|
|
Number of participants receiving in each category of mean OCS dose during the last 4 weeks of study treatment period (Weeks 49 to 52)
Lasso di tempo: Weeks 49 to 52
|
Number of participants receiving the mean OCS dose (categorized as 0, >0 to <=4, >4 to <=7.5 or >7.5 mg/day) will be assessed during the last 4 weeks of the study treatment period (Weeks 49 to 52). |
Weeks 49 to 52
|
|
Number of participants in each category of accrued duration of remission according to the EULAR definition of remission (BVAS = 0 plus OCS <=7.5 mg/day) over 52-week intervention period
Lasso di tempo: Up to Week 52
|
Total accrued duration of remission according to the EULAR definition of remission is the accrued number of weeks where BVAS = 0 plus OCS dose <=7.5 mg/day over the 52 week intervention period categorized as zero weeks; >0 to <12 weeks; 12 to <24 weeks; 24 to <36 weeks or >= 36 weeks. |
Up to Week 52
|
|
Number of participants with total accrued duration of remission according to the EULAR definition of remission
Lasso di tempo: Up to Week 52
|
Total accrued duration of remission according to the EULAR definition of remission is the accrued number of weeks where BVAS=0 plus OCS <=7.5 mg/day over the 52-week intervention period. |
Up to Week 52
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: GSK Clinical Trials, GlaxoSmithKline
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie vascolari
- Malattia cardiovascolare
- Malattie autoimmuni
- Malattie del sistema immunitario
- Malattie della pelle
- Malattie linfatiche
- Malattie linfoproliferative
- Malattie della pelle, vascolari
- Vasculite
- Vasculite associata ad anticorpi citoplasmatici anti-neutrofili
- Granulomi
- Vasculite sistemica
- Malattie della pelle e del tessuto connettivo
- Malattie emiche e linfatiche
- Sindrome di Churg Strauss
- mepolizumab
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 217102
- 2023-510019-20-00 (Altro identificatore: EU CT Number)
- 2021-005726-15 (Identificatore di registro: EudraCT (EU))
- 2023-510019-20-00 (Identificatore di registro: CTIS (EU))
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
IPD for this study will be made available via the Clinical Study Data Request site.
Periodo di condivisione IPD
IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Criteri di accesso alla condivisione IPD
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .